{
  "id": "starkage-therapeutics-and-gustave-roussy-team-up-to-advance-senolytic-cancer-therapies",
  "title": "StarkAge Therapeutics and Gustave Roussy team up to advance senolytic cancer therapies",
  "summary": "StarkAge Therapeutics, a French biotechnology company developing senolytic antibody-drug conjugates, announced a research collaboration with Gustave Roussy, Europe’s leading cancer centre, to accelerate development of STX-1, a first-in-class senolytic therapy for digestive cancers, the companies said. The partnership is designed to characterise cellular senescence induced by standard-of-care treatments across a broad set of digestive tumours […] The post StarkAge Therapeutics and Gustave Roussy team up to advance senolytic cancer therapies appeared first on Longevity.Technology.",
  "url": "https://longevity.technology/news/starkage-therapeutics-and-gustave-roussy-team-up-to-advance-senolytic-cancer-therapies/",
  "source": "Longevity.Technology",
  "author": null,
  "category": "news",
  "publishedAt": "2026-01-28T17:31:25.000Z",
  "fetchedAt": "2026-02-04T10:49:05.820Z",
  "relevanceScore": 0.7,
  "matchedKeywords": [
    "longevity",
    "senolytic",
    "senescence"
  ],
  "relatedProducts": [
    "fisetin",
    "quercetin"
  ],
  "type": "web",
  "savedAt": "2026-02-04T10:49:05.850Z"
}